Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...
Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback